Search results for "School."

showing 10 items of 4295 documents

Door-to-door prevalence survey of epilepsy in three Sicilian municipalities

2001

A door-to-door prevalence survey of epilepsy was conducted in 3 Sicilian municipalities, as of November 1, 1987. In phase 1, the screening by questionnaire of 24,496 eligible subjects (participation = 92%) identified 544 suspected to have epilepsy. In phase 2, neurological evaluation of the 544 subjects yielded 111 with epilepsy. Of the 111 subjects, 103 (93%) had been previously diagnosed, 68 (61%) were taking antiepileptic medication, and 81 (73%) had active epilepsy. Referring to the 81 subjects with active epilepsy, the seizure type was generalized in 60 (74%), partial in 19 (23%) and undetermined in 2 (3%). The prevalence of active epilepsy (per 1,000 population) was 3.3 overall, 3.5 f…

AdultMalePediatricsmedicine.medical_specialtyAdolescentEpidemiologyPopulationEpilepsySeizuresPrevalenceMedicineHumanseducationSurveyChildSicilyAgedAged 80 and overeducation.field_of_studyEpilepsybusiness.industryAge FactorsPrevalence surveyMiddle Agedmedicine.diseaseHealth Surveyslanguage.human_languageChild PreschoollanguageScreeningSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessSicilian
researchProduct

Ophthalmic Outcomes of Congenital Toxoplasmosis Followed Until Adolescence

2014

BACKGROUND: Congenital toxoplasmosis (CT) can elicit severe damage to several organs, especially the eye, and may be manifested at birth or later. We assessed the long-term ocular prognosis in a cohort of congenitally infected children treated according to a standardized protocol and monitored for up to 22 years. METHODS: This prospective study included confirmed cases of CT, which were identified by obligatory antenatal screening at the Lyon (France) reference center between 1987 and 2008. Data obtained through ocular examinations were recorded on a standardized form and confirmed by an independent external committee. Risk factors for retinochoroiditis were identified by using a multivari…

AdultMalePediatricsmedicine.medical_specialtyAdolescentEye DiseasesToxoplasmosis CongenitalCohort StudiesLesionYoung AdultPregnancyHumansMedicineProspective StudiesChildProspective cohort studybusiness.industryProportional hazards modelChorioretinitisInfantmedicine.diseaseCongenital toxoplasmosisMaternal infectionTreatment OutcomeChild PreschoolPregnancy Complications ParasiticPediatrics Perinatology and Child HealthCohortOcular lesionFemaleFrancemedicine.symptombusinessFollow-Up StudiesPediatrics
researchProduct

Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: Report of seven new cases.

2019

Alpha-mannosidosis (AM) is a very rare (prevalence: 1/500000 births) autosomal recessive lysosomal storage disorder. It is characterized by multi-systemic involvement associated with progressive intellectual disability, hearing loss, skeletal anomalies, and coarse facial features. The spectrum is wide, from very severe and lethal to a milder phenotype that usually progresses slowly. AM is caused by a deficiency of lysosomal alpha-mannosidase. A diagnosis can be established by measuring the activity of lysosomal alpha-mannosidase in leucocytes and screening for abnormal urinary excretion of mannose-rich oligosaccharides. Genetic confirmation is obtained with the identification of MAN2B1 muta…

AdultMalePediatricsmedicine.medical_specialtyAdolescentHearing lossAlpha-mannosidosisUrinary systemYoung Adultalpha-MannosidaseIntellectual DisabilityIntellectual disabilityExome SequencingGeneticsmedicineHumansChildHearing LossGenetics (clinical)Exome sequencingCoarse facial featuresbusiness.industrySiblingsEnzyme replacement therapymedicine.diseaseHypotoniaPhenotypeChild Preschoolalpha-MannosidosisFemalemedicine.symptombusinessLysosomesAmerican journal of medical genetics. Part A
researchProduct

Association of childhood cancer with factors related to pregnancy and birth

1999

It has been hypothesized that risk factors of childhood cancers may already operate during the prenatal and neonatal period. Results of previous epidemiological studies have been inconsistent.During 1992-1997 a large case-control study on childhood cancers and a variety of potential risk factors was conducted in Germany. Cases were ascertained by the German Childhood Cancer Registry. Each case was matched to a population-based control of the same age and gender, sampled from the district where the case lived at the date of diagnosis. For the analyses, 2358 cases and 2588 controls were available.Risk of childhood acute leukaemia increased with maternal ageor =20 years at time of delivery (od…

AdultMalePediatricsmedicine.medical_specialtyAdolescentHormone Replacement TherapyEpidemiologyBirth weightPopulationBone NeoplasmsSoft Tissue NeoplasmsPrenatal careCentral Nervous System NeoplasmsPregnancyRisk FactorsGermanyOdds RatiomedicineBirth WeightHumansRegistriesRisk factorChildeducationRetrospective Studieseducation.field_of_studyChildhood Cancer RegistryPregnancybusiness.industryLymphoma Non-HodgkinSmokingInfant NewbornCase-control studyInfantGeneral MedicineOdds ratioPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseParityMaternal ExposureChild PreschoolPrenatal Exposure Delayed EffectsFemalebusinessMaternal AgeInternational Journal of Epidemiology
researchProduct

The impact of ten years of infant universal Varicella vaccination in Sicily, Italy (2003-2012).

2015

Introduction Universal varicella vaccination in Sicily was introduced in infant population since 2003, with a rapidly increasing coverage. Aim of the present study was to analyze changes in the epidemiology of varicella since the introduction of universal vaccination. Methods The study was performed by analyzing Sicilian administrative/clinical data on varicella case notifications and hospitalizations from 2003 to 2012 (ICD-9-CM discharge diagnosis codes 052 and 052.×). MMR+V and V coverage were also calculated for each birth cohort. Moreover, blood samples drawn in 2013/2014 from general population stratified by age were tested for varicella antibodies. Results From 2003 to 2012, 15 433 va…

AdultMalePediatricsmedicine.medical_specialtyAdolescentImmunologyPopulationSocio-culturalecoverageVaricella vaccinationAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataChickenpox VaccineYoung AdultChickenpoxvaricellaEpidemiologyHumansImmunology and AllergyMedicineYoung adultChildeducationDisease NotificationSicilyChickenpox VaccineHospitalizationsPharmacologyeducation.field_of_studyChickenpoxbusiness.industryVaccinationInfant NewbornInfantNotificationsmedicine.diseaseHospitalizationVaccinationCoverage; Epidemiology; Hospitalizations; Notifications; Sicily; Universal mass vaccination; VaricellaChild PreschoolFemaleepidemiologynotificationbusinessBirth cohortuniversal mass vaccinationHumanResearch Paperhospitalization
researchProduct

Immunity to tetanus in the 3-20 year age group in Italy

1997

In Italy, systematic mandatory tetanus immunization of children started in 1968. In 1989, immunity against tetanus was assessed in a random sample of 758 healthy subjects aged 3-20 y, from four Italian cities. There were 257 subjects 3-5 y old all residing in Southern Italy and 501 subjects 11-20 y old from both the South and North. The overall prevalence of non-immune subjects was 19.1%, without difference by sex. The rates of subjects lacking protective antibody titres was 25.3% in children 3-5 y old (all coming from South and the islands), 11.5% in those 11 y old, and 18.9% in the 18-20 y age-group, respectively. Subjects 11-20 y old residing in the South and the islands were more likely…

AdultMalePediatricsmedicine.medical_specialtyAdolescentTetanus immunizationTetanus.ImmunitymedicinePrevalenceTetanus ToxoidHumansChildHigh rateTetanusTetanusbusiness.industryPublic Health Environmental and Occupational HealthHealthy subjectsImmunityGeneral Medicinemedicine.diseaseAntibodies BacterialVaccinationItalyChild PreschoolFemaleProtective antibodyGeographical inequalitiesbusiness
researchProduct

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

2014

Background: Meningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up program involving subjects up to 20 years of age. Catch-up was important, not only because it prevented disease in adolescents and young adults at risk, but also because it decreased transmission of the bacteria, since it was in this age group where the organism was circulating. Our objective is to develop a new vaccination schedule to achieve maximum seroprotection in these groups. Methods: A recent study has provided detailed age-structured information on the seroprote…

AdultMalePediatricsmedicine.medical_specialtyAdolescentVaccination scheduleMeningococcal VaccinesDiseaseBooster doseMeningococcal vaccineVaccination programsYoung AdultMeningococcal C conjugate vaccinesmedicineHumansYoung adultChildImmunization Programsbusiness.industryIncidence (epidemiology)VaccinationSeroprotection studyMiddle AgedAgent-based modellingMeningococcal InfectionsVaccinationInfectious DiseasesImmunizationSpainChild PreschoolFemaleMATEMATICA APLICADAbusinessResearch ArticleBMC Infectious Diseases
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome

2011

Background:  To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Methods:  Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months). Results:  Fifteen of 38 patients (39.5%) had a ≥50% seizure reduction in co…

AdultMalePediatricsmedicine.medical_specialtyAdolescentrufinamideRufinamideIrritabilityrefractory seizures; rufinamide; epileptic encephalopathies-childhoodYoung AdultRefractoryepileptic encephalopathies-childhoodrefractory seizuresrufinamideMedicineHumansYoung adultAdverse effectChildPreschoolepileptic encephalopathies-childhoodBrain DiseasesEpilepsybusiness.industryEpileptic encephalopathies-childhood; Refractory seizures; RufinamideTriazolesmedicine.diseaseSettore MED/39 - Neuropsichiatria Infantilerefractory seizuresMigraineepileptic encephalopathies-childhood refractory seizures rufinamideNeurologyAnesthesiaChild PreschoolVomitingAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessEpileptic encephalopathies-childhood; Refractory seizures; Rufinamide; Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child Preschool; Epilepsy; Female; Humans; Male; Triazoles; Young Adult; Neurology (clinical); NeurologyLennox–Gastaut syndromemedicine.drug
researchProduct